Abstract
王志高,周伟忠,史鉴,王同来.伤寒Vi多糖菌苗流行病学效果观察[J].Chinese journal of Epidemiology,1997,18(1):26-29
伤寒Vi多糖菌苗流行病学效果观察
Efficacy and side Effects Following Immunization with Salmonella typhi Vi Capsular Polysaccharide Vaccine
Received:July 02, 1996  Revised:September 21, 1996
DOI:
KeyWord: 伤寒杆菌  伤寒Vi多糖菌苗
English Key Word: Salmonella typhi  Vi capsular polysaccharide vaccine
FundProject:
Author NameAffiliation
Wang Zhi-gao Jiangsu Provincial Hygiene and Epidemic Prevention Station, Nanjing 210024 
Zhou Wei-zhong Jiangsu Provincial Hygiene and Epidemic Prevention Station, Nanjing 210024 
Shi Jian 扬州市卫生防疫站 
王同来 宝应县卫生防疫 
Hits: 1064
Download times: 264
Abstract:
      对我国研制的伤寒Vi多糖菌苗进行接种反应及流行病学效果观察,并以其稀释液作为对照,对777名接种者的反应观察结果表明,菌苗组发热弱、中反应率分别为16.93%和0.05%,对照组分别为15.01%和0.03%.两者发热反应率无显著差异。菌苗组仅出现2例局部轻反应。对81506名接种者观察,以血培养伤寒杆菌阳性作为病人诊断标准,菌苗的保护指数为3.49,保护率为71.35%。临床资料显示,接种组发病者的发热强度明显低于对照组发病者。作者认为该苗全身、局部反应轻微,安全性好,保护率较高,发病者可降低发热强度,且初免只需注射一针,是一种值得推广使用的新一代菌苗。
English Abstract:
      Efficacy and side effects following the immunization with Salmonella typhi Vi capsular polysaccharide vaccine (Vi) were assessed. The diluted solution (DS) of V was used as placebo. A total number of 777 children and adults were observed for side effect response. Mild and moderate fever appeared 16.93% and 0.05% in Vi group, 15.01% and 0.03% in DS group, respectively (statistically significant). Two cases with mild local reaction were observed in Vi group. A total number of 81506 vaccinees were investigated on the efficacy of Vi vaccine, using positive blood culture of Salmonolla typhi as a diagnostic criterion. The protective rate and index of vaccine were 71.35% and 3, 49% respectively.If 2 cases of positive Widal's test were included in, the protective rate would come up to 78.17% with a protective index 4.85. Clinical data showed that fever seen in the cases in Vi group was much lower than that of DS group. The systematic and local reaction of Vi vaccine were mild. The vaccine is safe and has high protective rate. It can also decrease the degree of fever with only one single dose as primary immunization. We believe Vi vaccine may serve as a vaccine of new generation to be promoted.
View Fulltext   Html FullText     View/Add Comment  Download reader
Close